-
Revue Medicale de Bruxelles Sep 1985
Review
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Prognosis; Retrospective Studies; Vincristine
PubMed: 2417298
DOI: No ID Found -
The New England Journal of Medicine Dec 2009
Comparative Study
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Follow-Up Studies; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; Procarbazine; Survival Analysis; Vinblastine; Vincristine
PubMed: 20007568
DOI: 10.1056/NEJMc0906731 -
Journal of Clinical Oncology : Official... Feb 1999
Clinical Trial Comparative Study Randomized Controlled Trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; Procarbazine; Vinblastine; Vincristine
PubMed: 10080622
DOI: 10.1200/JCO.1999.17.2.730a -
Gan To Kagaku Ryoho. Cancer &... Dec 1998Systemic polychemotherapy and local radiation are two well-established treatments for Hodgkin's disease. With the use of modern techniques, the great majority of... (Review)
Review
Systemic polychemotherapy and local radiation are two well-established treatments for Hodgkin's disease. With the use of modern techniques, the great majority of patients with pathologic stage I-II Hodgkin's disease can be cured with irradiation alone. Since the invention of the MOPP and ABVD schemes, polychemotherapy has become indispensable for the treatment of advanced-stage Hodgkin's disease. The role of radiotherapy in combination with chemotherapy is limited to specific indications. ABVD therapy is as effective as MOPP alternating with ABVD, and both are superior to MOPP alone in the treatment of advanced Hodgkin's disease. MOPP/ABVD hybrid chemotherapy was significantly more effective than sequential MOPP-ABVD in 8-year failure-free survival and overall survival. The patients with advanced-stage Hodgkin's disease who did not achieve a complete remission from their initial treatment with combination chemotherapy have a dismal prognosis. Those whose initial remissions had lasted longer than 12 months had a very high probability of obtaining a second complete remission when re-treated with MOPP or ABVD, but those whose remission lasted less than 12 months fared less well with any conventional-dose chemotherapy. High-dose chemotherapy and radiotherapy with autologous hemopoietic stem cell transfusion are superior in the treatment of those whose disease is refractory or resistant to the initial therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Mechlorethamine; Prednisone; Procarbazine; Vinblastine; Vincristine
PubMed: 9881076
DOI: No ID Found -
Radiotherapy and Oncology : Journal of... Nov 1986299 patients with stage III or IV Hodgkin's disease were randomised to receive cyclical chemotherapy with MOPP (mustine, Oncovin, procarbazine, prednisone) or LOPP... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation.
299 patients with stage III or IV Hodgkin's disease were randomised to receive cyclical chemotherapy with MOPP (mustine, Oncovin, procarbazine, prednisone) or LOPP (Leukeran substituted for mustine). The complete remission rates (59.9% for MOPP, 59.4% for LOPP), actuarial survival (65.7 and 68.2% at 5 years, respectively) and complete remission/relapse free survival (33.3 and 32.2% at 5 years, respectively) were similar for both groups. There were no significant differences in response data between the MOPP and LOPP groups for individual prognostic variables (histology grade, stage, age and response to treatment). Deaths in both groups were usually due to disseminated Hodgkin's disease with terminal infection; there were no infective deaths in the absence of Hodgkin's disease. The less toxic regimen of LOPP can therefore be expected to produce results similar to those seen with MOPP, and this is true regardless of the severity of the illness.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Random Allocation; Vincristine
PubMed: 3544084
DOI: 10.1016/s0167-8140(86)80032-9 -
Japanese Journal of Clinical Oncology May 2008Chemotherapy with or without radiotherapy is the mainstay of treatment for primary central nervous system lymphoma (PCNSL). High-dose methotrexate (MTX) is the most...
BACKGROUND
Chemotherapy with or without radiotherapy is the mainstay of treatment for primary central nervous system lymphoma (PCNSL). High-dose methotrexate (MTX) is the most effective drug available to treat these lesions, either as a single agent or in combination with other drugs. Due to the lack of well-conducted randomized trials, the optimal treatment remains controversial. Available retrospective studies are difficult to discuss, however, some common themes can be found.
METHODS
One hundred and twelve patients with PCNSL were treated with four different regimens over a period of 24 years. Treatment regimens were: whole-brain irradiation (WBI) alone, MVP (MTX, vincristine, and predonisolone), ProMACE-MOPP hybrid (cyclophosphamide, pirarubicin, etoposide, vincristine, procarbazine, prednisone, and MTX) and R-MTX (rituximab, MTX, pirarubicin, procarbazine, and prednisone) combined-modality therapy.
RESULTS
The median failure-free survival was 16 months, and the median overall survival (OS) was 24 months. The 2- and 5-year actuarial probability of survival was 52.4 +/- 4.8% [95% confidence intervals (CI)] and 30.2 +/- 4.8% (95% CI), respectively. The ProMACE-MOPP protocol, Karnofsky performance status (KPS), MTX dose and WBI were associated with good OS by univariate models. By multivariate analysis, MTX dose, WBI dose, and its square dose were significantly associated with good OS. 20-30 Gy WB, and 500 mg/m(2) of MTX dose appeared important determinants of OS.
CONCLUSIONS
A modest dose of MTX (500 mg/m(2)) followed by reduced-dose WBI for patients who respond appears a feasible treatment approach that minimizes serious toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Cognition; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Leucovorin; Lymphoma; Male; Mechlorethamine; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine
PubMed: 18413337
DOI: 10.1093/jjco/hyn027 -
European Journal of Cancer & Clinical... Sep 1982
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Dacarbazine; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Prednisone; Procarbazine; Vinblastine; Vincristine
PubMed: 6185342
DOI: 10.1016/0277-5379(82)90188-2 -
Cancer Investigation 1988Patients with advanced Hodgkin's disease not achieving a complete remission with initial MOPP therapy are significantly less responsive to adriamycin and... (Review)
Review
Semantics and the chemotherapy of Hodgkin's disease--resistance is not relapse: alternative chemotherapy lacks effectiveness for disease not totally responsive to initial MOPP treatment.
Patients with advanced Hodgkin's disease not achieving a complete remission with initial MOPP therapy are significantly less responsive to adriamycin and nitrosourea-containing regimens than patients with relapsing disease following a complete remission with MOPP. Hodgkin's disease not responding completely to initial four-drug treatment represents resistant disease which, in most instances, may not be cured with existing alternative chemotherapy. These patients should receive innovative treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; Procarbazine; Recurrence; Remission Induction; Vincristine
PubMed: 3288299
DOI: 10.3109/07357908809077052 -
Pediatric Blood & Cancer Nov 2008
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; Procarbazine; Prognosis; Radiotherapy; Survival Analysis; Vincristine
PubMed: 18668513
DOI: 10.1002/pbc.21649 -
Cancer Mar 1989The toxicity of MOPP chemotherapy, including nausea, vomiting, hair loss, and neuropathy, can limit patient compliance. Alternative regimens employing oral alkylating...
The toxicity of MOPP chemotherapy, including nausea, vomiting, hair loss, and neuropathy, can limit patient compliance. Alternative regimens employing oral alkylating agents and vinblastine have been designed to ameliorate these toxicities. The authors reviewed their experience in 24 patients with advanced-stage Hodgkin's disease who were treated with chlorambucil, vinblastine, procarbazine, and prednisone (ChlVPP). Complete responses were obtained in 92% (11/12) of previously untreated patients and in 92% (11/12) of patients who relapsed after radiation (10/10) or chemotherapy (one of two). Overall, relapse-free survival is 82% with a median duration of follow-up of 5.5 years. Toxicity was minimal with myelosuppression being the dose-limiting toxicity. Severe nausea and vomiting occurred in only two patients and was considered secondary to procarbazine. Mild nausea occurred in six other patients. Minimal alopecia was seen in three patients and only two patients developed a mild peripheral neuropathy. The authors conclude that ChlVPP appears as effective as MOPP chemotherapy for Hodgkin's disease in comparable presentations but is a less toxic regimen. Thus, it may be useful in situations where poor compliance and patient acceptance may compromise optimal dose and frequency of drug administration.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Chlorambucil; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Neoplasm Staging; Neutropenia; Prednisolone; Prednisone; Procarbazine; Recurrence; Remission Induction; Vinblastine; Vincristine
PubMed: 2917308
DOI: 10.1002/1097-0142(19890315)63:6<1060::aid-cncr2820630603>3.0.co;2-m